Antibody technology – discover R&D, business analysis, and revenue forecasts
What’s the future of technologies harnessing therapeutic antibodies? Now you can get technological and business predictions. Stay ahead for data, helping your authority. There you explore developmental trends, sales results, opportunities, and revenue forecasts.
Visiongain’s new report shows you what’s possible for monoclonal antibodies (mAbs) and other immunotechnology for pharmaceuticals. Avoid missing out. Instead find progress in that medical industry and market, discovering the expected progress and gains.
Read on to explore those drugs, seeing how high revenues can go.
Forecasts and other information showing lucrative biopharmaceutical possibilities
The updated study gives you sales predictions to 2024 at overall world, submarket, product, and regional level. For those treatments – antibodies and variants – you investigate where money lies.
Hear what’s possible. Also avoid struggles to find information. Besides revenue forecasting, our new work shows historical performance, recent results, growth rates, and market shares. There you also gain feel for developments (R&D) in those medicines.
So discover 74 tables, 58 charts, and three interviews with authorities in that industry, helping your research, analyses, and decisions.
And the following sections explain what our investigation gives you.
Forecasting of that world market and its main segments – what’s likely to happen?
What’re the secrets of that biomedical industry’s progress? Discover in our report overall world revenue to 2024 for those immunological products.
Also find individual revenue predictions to 2024 for five therapeutic submarkets at world level:
• Antibody-drug conjugates (ADCs)
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and antibody-like proteins (ALPs)
• Biosimilar antibodies (biosimilars).
There you assess outlooks for sales expansion, hearing where you could gain. Our work investigates R&D, competition and rising sales – technological and commercial possibilities.
You explore successes, developments and competition for those biological drugs (biologics). And you find leading therapeutic agents’ selling potentials.
Revenue predictions for top therapeutics in that biotechnological segment
How will individual drugs perform to 2024 at world level? Our study forecasts revenues of six products:
• Adcetris
• Kadcyla
• Poteligeo
• Gazyva
• Removab
• Kalbitor.
And these four biosimilar agents:
• Rituximab
• Infliximab
• Trastuzumab
• Adalimumab.
There you find drugs and years with highest predicted sales. Also you examine competitors. You see what’s happening, then, understanding, challenges, trends, and outlooks.
That work also shows geographical revenue predictions.
Healthcare in regional markets – what outlooks for follow-on antibodies?
In developed and developing countries, many opportunities for producers and sellers of next-generation antibody products will occur from 2014 to 2024. See where and how.
Our analyses show you individual revenue forecasts to 2024 for four regional markets:
• United States (US)
• Japan
• European Union (EU)
• Rest of world (grouped).
There you find countries with highest revenues, demand, and potential sales growth. Explore progress, needs and opportunities.
What events, challenges and expectations affect that industry and market? Our work shows you, discussing events, policies, and trends influencing that pharma field.
Forces affecting developers, producers, and sellers of those immunotechnological agents
The report explains issues and events affecting that industry and market from 2014, including these:
• Improved monoclonal antibodies, Fab fragments, and receptor constructs
• Drug approvals and outlooks
• Acquisitions by big pharmaceutical companies
• R&D pipelines for new therapies – e.g. CD19, CD20, and HER targeting – including biosuperiors
• Cancer treatments – ovarian, breast, prostate, lymphoma, and leukaemia.
And you explore these influences, among others:
• Modifying amino acids in the Fc domain
• Recombinant antibody mixtures – improving therapeutic proteins
• Single-chain variable fragment platforms
• Product lifecycle management and regulatory affairs
• Contract manufacturing organisations (CMOs) investing in next-generation antibody technologies.
See too how R&D lets companies benefit patients. You find what stimulates and restrains players in that sector, and affects its results.
New antibody technology and applications – companies and 2018 market value
From 2014, novel treatments and demands from patients, doctors, and payers encourage investments, medical advances, and higher revenues from immune-based technologies.
And what happens next? Our study predicts that world market will reach $6.7bn in 2018.
There you examine activities of many companies, including these:
• Roche
• Pfizer
• Seattle Genetics
• Amgen
• Kyowa Hakko Kirin
• ImmunoGen.
You find 180 organisations covered. You also get three interviews with leaders in that industry. Discover what participants do, say, and think, helping you stay ahead.
Ways Next-Generation Antibody Therapies: World Industry and Market 2014-2024 helps
Through knowledge such as this, our new report helps you gain recognition for insight:
• Revenues there to 2024 at world level, for 5 submarkets, and 10 products – assess outlooks for production, marketing, and sales
• Forecasts to 2024 for four regional markets – investigate leading regions and countries for revenues and sales expansion
• Prospects for established competitors, rising companies, and new entrants – explore portfolios, results, strategies, R&D, and outlooks for success.
Information found nowhere else, helping your searches, analyses, and planning
Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where money and progress lie. You explore the business possibilities.
With that data you’re less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find with our report how you could save time and effort. And also help your plans, decisions, influence, and competing.
Our new report is for everyone analysing medical biotechnology. There you explore crucial trends, finding sales potentials from 2014. So avoid missing out – please order now.
To see sample pages of this report please click here
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Executive Summary
1.1 Next-Generation Therapies: World Market Review 2014
1.2 Report Contents
1.2.1 Benefits of this Report
1.3 Study Methods
1.3.1 Financial Information in this Report
1.3.2 Who is this Report for?
1.4 Introduction to Next-Generation Antibodies
1.4.1 Defining Next-Generation Antibodies
1.4.2 A Brief History of Antibody Drug Development
1.4.3 The Need for Next-Generation Technologies
1.4.4 Development Trends for Next-Generation Antibodies
2. The World Next-Generation Antibody Therapies Market: Outlook and Forecast 2014-2024
2.1 The Next-Generation Antibody Therapies Market 2012-2023
2.1.1 Leading Sectors of the Next-Generation Antibody Therapies Market 2012-2013
2.1.1.1 There Are Products Approved in All Market Sectors
2.1.2 Next-Generation Antibodies in the Overall Antibody Market
2.2 The Next-Generation Antibody Therapies Market 2014-2024
2.2.1 Growth in the Antibody Therapies Market 2014-2024
2.2.2 Next-Generation Antibody Therapies: Market Forecast 2014-2024
2.2.3 Approvals in All Market Sectors Will Drive Growth to 2024
2.2.4 High Levels of Competition Will Restrain Growth in this Decade
2.2.5 ADCs Lead the Market in 2014
2.2.5.1 ADCs Will Account for 40% in 2018
2.2.5.2 What Will Be the Leading Market Sector in 2024?
2.3 Leading National Markets for Next-Generation Antibody Therapies 2014-2024
2.3.1 The US Leads the Market in 2014
2.3.1.1 US Submarket Forecast 2014-2024
2.3.2 Next Generation Antibodies in the EU 2014-2024
2.3.3 The Japanese Submarket 2014-2024
2.3.4 Demand for Next-Generation Antibody Therapies in Emerging National Markets
3. Antibody-Drug Conjugates (ADCs): Pipeline and Commercial Outlook 2014-2024
3.1 ADC Submarket 2012-2013
3.1.1 Two Products Launched Since 2011
3.1.2 Mylotarg: The First ADC Is No Longer Marketed
3.2 ADC Submarket 2014-2024
3.2.1 ADC Submarket Forecast 2014-2024
3.2.2 ADC Submarket Drivers: A Long and Growing R&D Pipeline
3.2.3 Competition for Leading Drugs Will Restrain Growth 2014-2024
3.2.3.1 Manufacturing ADCs Forms a Challenge
3.3 Adcetris (Brentuximab Vedotin, Seattle Genetics/Takeda)
3.3.1 Expanding the Label for Future Revenue Growth
3.3.2 Adcetris: Revenue Forecast 2014-2024
3.4 Kadcyla (Trastuzumab Emtansine, Roche)
3.4.1 Part of Roche's HER2 Portfolio
3.4.2 Kadcyla: Revenue Forecast 2014-2024
3.5 Two Platforms Dominate the Pipeline in 2014
3.5.1 Seattle Genetics' Platform Accounts for 60% of the Clinical Pipeline
3.5.2 ImmunoGen: TAP Technology
3.5.3 Leading Biotechs Are Assessing Both Platforms
3.5.4 Other Platforms for ADC Development
3.5.4.1 Immunomedics: Lower Potency Cytotoxics for Extended Use
3.5.4.2 Synthon Biopharmaceuticals
3.5.5 ADCs Are Attracting High Value Deals
3.6 ADC Pipeline: Outlook 2014-2024
3.6.1 The Longest Pipeline in the Next-Generation Antibodies Market
3.6.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
3.6.3 Pfizer's CMC544 Is the Only Phase III Candidate
3.6.4 Roche Has Eight Clinical-Stage Candidates
3.6.4.1 RG7593 and RG7596: ADCs for NHL
3.6.4.2 Three Candidates for Ovarian Cancer
3.6.4.3 RG7450 for Prostate Cancer
3.6.5 CDX-011: Another ADC for Breast Cancer Patient Subsets
3.6.6 SAR3419 (Sanofi): Targeting CD19 in Lymphoma
3.6.7 BT-062 (Biotest)
3.6.8 Immunomedics: Two Phase II ADCs from its Proprietary Platform
3.6.9 PSMA ADC (Progenics Pharmaceuticals): A Second Candidate for Prostate Cancer
3.6.10 ABT-414 (AbbVie)
3.6.11 Seattle Genetics: Three Phase I Candidates
3.6.11.1 SGN-CD33A: Using a New Cytotoxin and Linker Technology
3.6.12 Astellas Pharma: Partnered with Seattle Genetics for Phase I ADCs
3.6.13 ImmunoGen: Three Phase I Candidates
3.6.14 SAR566658 (Sanofi)
3.6.15 MLN0264 (Millennium Pharmaceuticals)
3.6.16 AMG 595 (Amgen)
3.6.17 BAY 94-9343 (Bayer)
3.6.18 AMG 172 (Amgen)
3.6.19 PF-06263507 (Pfizer)
3.6.20 HuMax-TF-ADC (Genmab)
3.7 Future Developments in ADC Technology
3.7.1 Site-Specific Linkage for Improved Safety Profiles
4. The Engineered Antibodies Submarket 2014-2024
4.1 The Engineered Antibodies Submarket 2012-2013
4.1.1 Two Engineered Antibodies Approved 2012-2013
4.2 The Engineered Antibodies Submarket Forecast 2014-2024
4.2.1 What Will Drive Submarket Growth to 2024?
4.2.2 Engineered Antibodies: Submarket Restraints 2014-2024
4.3 Poteligeo: The First Engineered Antibody Is Only Available in Japan
4.3.1 Poteligeo: Revenue Forecast 2014-2024
4.4 Gazyva: A Follow-On to Roche's Marketing-Leading Rituxan
4.4.1 Gazyva as a Challenger in the anti-CD20 Market
4.4.1.1 Competition beyond Rituxan and Biosimilars
4.4.2 Gazyva: Revenue Forecast 2014-2024
4.5 Leading Technology Platforms for Engineered Antibodies 2014-2024
4.5.1 Enhancing ADCC: The Potelligent Platform
4.5.2 Roche Glycart: Glycosylation for Improved ADCC
4.5.3 XmAb (Xencor): Modifying Amino Acids in the Fc Domain
4.5.4 Other Platforms for Increased Potency
4.5.4.1 GlycoExpress (Glycotope)
4.6 Engineered Antibodies Pipeline 2014
4.6.1 Pipeline Changes 2011-2013
4.6.2 Benralizumab (MedImmune/Kyowa Hakko Kirin)
4.6.3 Margetuximab (MacroGenics)
4.6.4 MEDI-551: MedImmune and Kyowa's Second Collaboration
4.6.5 MOR-208 (Xencor/MorphoSys)
4.6.6 PankoMab-GEX: Glycotope's Lead Candidate
4.6.7 Teplizumab: Failed in Phase III but Undergoing Phase II Investigator-Led Studies
4.6.8 Kyowa Hakko Kirin Has Four Early-Stage Candidates
4.6.9 Ocaratuzumab (Mentrik Biotech): Phase I for NHL
4.6.10 Ublituximab (TG Therapeutics/LFB)
4.6.11 XmAb5871 (Xencor/Amgen)
4.6.12 RG7116: A Future Addition to Roche's Breast Cancer Portfolio
4.6.13 CetuGEX and TrasGEX: Two Early-Stage Glycotope Biosuperiors
4.6.14 MGA271 (MacroGenics/Servier)
5. The Bispecific Antibodies Submarket: Commercial Potential 2014-2024
5.1 The Bispecific Antibodies Submarket 2012-2013
5.2 The Bispecific Antibodies Submarket 2014-2024
5.2.1 Commercial Outlook for Bispecific Antibodies: Revenue Forecast 2014-2024
5.2.2 Bispecific Antibodies: Submarket Drivers 2014-2024
5.2.3 Bispecific Antibodies: Submarket Restraints 2014-2024
5.2.3.1 Manufacturing Bispecific Antibodies: Maintaining Stability and Purification
5.3 Removab: The First Bispecific Antibody
5.3.1 Removab: Revenue Forecast 2014-2024
5.4 Many Platforms Are Under Investigation to Develop Bispecific Antibodies
5.4.1 BiTE Platform: The Current Market Leader
5.4.2 MacroGenics' DART Platform Holds Promise
5.4.3 TriomAbs (TRION Pharma): Limited Market Impact 2014-2024
5.4.4 ImmTAC (Immunocore)
5.4.5 DuoBodies (Genmab)
5.5 A Growing Pipeline for Bispecific Antibodies
5.5.1 Blinatumomab (Amgen): The Only Phase III Bispecific Antibody
5.5.1.1 The Outlook for Blinatumomab in ALL
5.5.2 Symphogen Has Two Phase II Candidates
5.5.2.1 Symphogen's Recombinant Antibody Mixtures
5.5.3 MM-111 (Merrimack Pharmaceuticals)
5.5.4 IMCgp100 (Immunocore)
5.5.5 BAY2010112 (Bayer)
5.5.6 MEDI-565: A Third BiTE Candidate
5.5.7 AFM13 (Affimed Therapeutics)
5.5.8 TF2: Utilising Immunomedics' Dock-and-Lock Platform
5.5.9 MM-141 (Merrimack Pharmaceuticals)
5.5.10 SAR156597 (Sanofi)
6. The Next-Generation Antibody Fragments and Antibody-Like Proteins (ALPs) Submarket 2014-2024
6.1 There Is One Marketed Product in 2014
6.1.1 Kalbitor (Ecallantide, Dyax)
6.1.1.1 Kalbitor: Revenue Forecast 2014-2024
6.2 Outlook for the Antibody Fragments and ALPs Submarket 2014-2024
6.2.1 Antibody Fragments and ALPs Submarket Forecast 2014-2024
6.2.2 Investment from Big Pharma Will Drive Growth 2014-2024
6.2.3 No Late-Stage Candidates to Restrain Growth to 2024
6.3 There Are Many Development Platforms in this Sector
6.3.1 Single-chain Variable Fragment Platforms
6.3.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
6.3.2 Nanobodies: The Smallest Antibody Fragment
6.3.2.1 Ablynx' Nanobody Platform Has Created Many Clinical Candidates
6.3.3 Domain Antibodies: GSK and Crescendo Biologics
6.3.4 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
6.3.4.1 DARPins: One Tenth the Size of Antibodies
6.3.4.2 Anticalins (Pieris): Tested in Clinical Trials
6.3.4.3 Affibodies
6.3.4.4 Fynomers (Covagen)
6.3.4.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development
6.3.4.6 Adnectins (Bristol-Myers Squibb)
6.3.5 Which Platform Will Lead the Market 2014-2024?
6.4 Clinical Development of Next-Generation Antibody Fragments and ALPs
6.4.1 Limited Activity for Five Clinical Candidates 2013-2014
6.4.2 Ablynx Leads the Pipeline with Seven Clinical Projects
6.4.2.1 ALX-0061: AbbVie Partners for RA Development
6.4.2.2 ALX-0141: A Next-Generation Osteoporosis Therapy
6.4.2.3 ALX-0761: A Third RA Candidate
6.4.3 AGN-150998: Development Delayed for Allergan's AMD Product
6.4.4 ESBA1008: An Ophthalmology Competitor in Phase II
6.4.5 DLX105 (Delenex Therapeutics)
6.4.6 GSK Has Two Early-Stage Candidates: GSK1995057 and GSK2374697
6.4.7 PRS-050 (Pieris): Targeting VEGF in Solid Tumours
7. The Biosimilar Antibodies Submarket 2014-2024
7.1 Biosimilar Antibodies Are the Target for Many Follow-On Biologics Developers
7.2 More Than Five Biosimilars Approved Worldwide in 2014
7.2.1 Biosimilar Antibodies Submarket 2013: Revenues from Emerging Markets Only
7.3 The Biosimilar Antibodies Submarket 2014-2024
7.3.1 Rapid Growth in Revenues Forecast from 2015 Onwards
7.3.2 Launches in the US and EU to Drive Growth to 2024
7.3.3 How Can Developers Ensure Uptake Among Physicians?
7.3.3.1 Automatic Substitution of Biosimilar Antibodies
7.3.4 Patent Expiries Will Hit Many Leading Antibodies in this Decade
7.3.5 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?
7.4 Biosimilar Rituximab 2014-2024
7.4.1 Reditux: The First Rituximab Biosimilar in the World
7.4.1.1 Mabtas: Biosimilar Competition in India
7.4.2 Kikuzubam: Biosimilar Competition for Roche in Latin America
7.4.3 Biosimilar Rituximab Pipeline 2014
7.4.3.1 Two Companies Halted Development 2012-2013
7.4.3.2 Celltrion: Development Delayed 2013
7.4.3.3 GP2013: Sandoz Is the Pipeline Leader
7.4.3.4 BI 695500 (Boehringer Ingelheim)
7.4.3.5 MabionCD20: Mabion Prepares Phase III for Developed Markets
7.4.3.6 BCD-020 (Biocad)
7.4.3.7 PF-05280586 (Pfizer)
7.4.4 Biosimilar Rituximab: Revenue Forecast 2014-2024
7.5 Biosimilar Infliximab: The First Target for Developed Markets
7.5.1 Inflectra/Remsima: Approved in South Korea and the EU
7.5.1.1 Flammegis: Egis Pharmaceuticals Markets the Biosimilar in Eastern Europe
7.5.2 Biosimilar Infliximab Pipeline 2014
7.5.2.1 BOW-015: Epirus Targets Emerging Markets First
7.5.2.2 Reliance Life Sciences: Biosimilar Infliximab in India
7.5.3 Biosimilar Infliximab: Revenue Forecast 2014-2024
7.6 Biosimilar Trastuzumab 2014-2024
7.6.1 CANMAb: The First Biosimilar Trastuzumab Approved in India
7.6.2 Herzuma: Approved in South Korea 2014
7.6.3 Fewer Clinical Candidates than for Biosimilar Rituximab 2014
7.6.3.1 Amgen and Actavis Advance to Phase III
7.6.3.2 Pfizer: A Third Candidate Set for Phase III
7.6.4 Biosimilar Trastuzumab: Revenue Forecast 2014-2024
7.7 Biosimilar Adalimumab 2014-2024
7.7.1 Humira Is the World's Leading Antibody Therapy
7.7.1.1 AbbVie Seeks to Protect its Lead Asset
7.7.2 Biosimilar Adalimumab Pipeline 2014
7.7.2.1 Amgen Advances to Phase III
7.7.2.2 Sandoz: A Second Phase III Candidate
7.7.2.3 Pfizer and Boehringer Ingelheim: Two Biosimilars in Phase I
7.7.3 Biosimilar Adalimumab: Revenue Forecast 2014-2024
8. Next-Generation Antibodies: Industry Trends 2014-2024
8.1 Next-Generation Antibodies: Strengths and Weaknesses 2014
8.1.1 Approved Products Indicate a Path to Market Acceptance
8.1.2 Challenges Exist With Current Monoclonal Antibody Therapies
8.2 Next-Generation Antibodies: Opportunities and Threats 2014-2024
8.2.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
8.2.2 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
8.3 Next-Generation Antibodies: STEP Analysis 2014-2024
8.3.1 Social Factors: Rising Demand for Cancer Therapies
8.3.1.1 Cancer Incidence Is Rising Rapidly
8.3.1.2 Next-Generation Antibodies for Personalised Medicine
8.3.2 Technological Developments Will Drive Pipeline Growth
8.3.2.1 There Are Many Competing Platforms
8.3.2.2 Manufacturing Challenges Exist for Most Sectors
8.3.2.3 New Analytical Tools for Target Identification and Protein Characterisation
8.3.3 Economic Pressures
8.3.3.1 Next-Generation Antibodies Are High-Cost
8.3.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
8.3.3.3 Next-Generation Launches for Product Lifecycle Management
8.3.4 Political and Regulatory Issues
8.3.4.1 Regulatory Challenges for Biosimilar Antibodies
8.4 Key Targets for Next-Generation Antibody Development 2014-2024
8.4.1 Oncology Is the Lead Indication in All Sectors
8.4.1.1 HER2 and HER3 for Breast Cancer
8.4.1.2 CD19 and CD20 for Lymphoma and Leukaemia
9. Research Interviews 2013-2014
9.1 Dr Edwin Moses, CEO, Ablynx
9.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
9.1.1.1 Manufacturing Nanobodies
9.1.2 Turning Challenges to Advantages
9.1.3 Nanobodies Are Further Developed than Other Antibody Scaffolds
9.1.4 The Commercial Potential for Nanobodies
9.1.5 Next-Generation Antibodies in China and Other Emerging Markets
9.2 Dr Marco Timmers, CSO, Synthon
9.2.1 Synthon
9.2.2.1 Second-Generation ADC Development
9.2.2 Key Benefits to Synthon's ADC Technology
9.2.2.1 Broader Use in HER2-Positive Disease
9.2.3 Clinical Development of Synthon's ADCs
9.2.4 Challenges in Developing ADCs
9.2.4.1 High Manufacturing Costs for Advanced Technologies
9.2.4.2 Regulatory Risks in ADC Development
9.2.5 Data Reporting for ADC Development
9.3 Dr Ivan Horak, CSO and CMO, Symphogen
9.3.1 Advantages of Antibody Mixtures
9.3.2 Activating the Immune System
9.3.3 Symphogen's Pipeline Outlook
9.3.4 The Next Ten Years
10. Conclusions to Our Study
10.1 The Next-Generation Antibody Therapies Market 2012-2013
10.1.1 ADCs Lead the Next-Generation Antibodies Market in 2014
10.2 Outlook for the Next-Generation Antibody Therapies Market 2014-2024
10.2.1 Growth in the Market 2014-2024
10.2.2 Commercial Drivers for Growth to 2024
10.2.3 Threats and Opportunities Exist in the Market 2014-2024
List of Tables
Table 1.1 Currency Exchange Rates, 2013
Table 1.2 Monoclonal Antibody Types and Sources, 2014
Table 2.1 Next-Generation Antibody Therapies Market: Revenues ($m), 2008-2013
Table 2.2 Next-Generation Antibody Therapies Market: Revenues ($m) and Market Shares (%) by Sector, 2012
Table 2.3 Next-Generation Antibody Therapies Approved, 2014
Table 2.4 Antibody Therapies Market: Revenues ($m) and Market Shares (%), 2012
Table 2.5 Antibody Therapies Market Forecast ($m), 2012-2024
Table 2.6 Next-Generation Antibodies Market: Overall Market and Revenue Forecasts ($m) by Sector, 2012-2024
Table 2.7 Next-Generation Antibody Therapies Market: Submarket Shares (%), 2012-2024
Table 2.8 Next-Generation Antibody Therapies Market: Revenues ($m) and Market Shares (%) by Country/Region, 2012
Table 2.9 Next-Generation Antibodies Market: Overall Market and Revenue Forecasts ($m) by Country/Region, 2012-2024
Table 2.10 US Next-Generation Antibody Therapies Submarket Forecast ($m), 2012-2024
Table 2.11 EU Next-Generation Antibody Therapies Submarket Forecast ($m), 2012-2024
Table 2.12 Next-Generation Antibody Therapies Market: Regional Submarket Shares (%), 2012-2024
Table 2.13 Japanese Next-Generation Antibody Therapies Submarket Forecast ($m), 2012-2024
Table 3.1 ADC Submarket: Revenues ($m) and Market Shares (%) by Drug, 2011-2013
Table 3.2 ADC Submarket: Overall Submarket and Revenue Forecasts ($m) by Drug, 2012-2024
Table 3.3 Adcetris: Revenue ($m) by Company, 2011-2013
Table 3.4 Adcetris: Revenue Forecast ($m), 2012-2024
Table 3.5 Kadcyla: Revenue ($m) by Region, Q1-Q4 2013
Table 3.6 Kadcyla: Revenue Forecast ($m), 2012-2024
Table 3.7 ADC Pipeline by Platform, 2014
Table 3.8 ImmunoGen: Collaboration Revenue ($m), 2012-2013
Table 3.9 Selected Pre-Clinical ADC Development Platforms, 2014
Table 3.10 Selected High-Value Deals for ADC Development, 2013-2014
Table 3.11 ADC Clinical Pipeline, 2014
Table 3.12 Selected Clinical Projects Discontinued, 2010-2013
Table 3.13 ADC Pipeline by Indication, 2014
Table 3.14 Ongoing Clinical Trials for CMC544, 2014
Table 4.1 Engineered Antibodies Submarket: Overall Submarket and Revenue Forecasts ($m) by Drug, 2012-2024
Table 4.2 Poteligeo: Revenue ($m), 2012-2013
Table 4.3 Poteligeo: Revenue Forecast ($m), 2012-2024
Table 4.4 Gazyva: Revenue Forecast ($m), 2012-2024
Table 4.5 Engineered Antibodies Pipeline by Technology Platform, 2014
Table 4.6 Selected Licensing Agreements for the Potelligent Platform and Cell Lines, 2008-2013
Table 4.7 Engineered Antibodies Pipeline, 2014
Table 4.8 Selected Clinical-Stage Engineered Antibody Projects Discontinued, 2010-2013
Table 5.1 Bispecific Antibodies Submarket: Overall Submarket and Revenue Forecasts ($m) by Drug, 2012-2024
Table 5.2 Removab: Revenue ($m), 2010-2013
Table 5.3 Removab: Revenue Forecast ($m), 2012-2024
Table 5.4 Selected Pre-Clinical Bispecific Antibody Platforms, 2014
Table 5.5 Selected MacroGenics Deals, 2010-2013
Table 5.6 Bispecific Antibodies Clinical Pipeline, 2014
Table 6.1 Kalbitor: Revenue ($m), 2011-2013
Table 6.2 Kalbitor: Revenue Forecast ($m), 2012-2024
Table 6.3 Antibody Fragments and ALPs Submarket: Overall Submarket and Revenue Forecasts ($m) by Drug, 2012-2024
Table 6.4 Ablynx: Selected Big Pharma Development Agreements, 2012-2014
Table 6.5 Antibody Fragments and ALPs Pipeline by Indication, 2014
Table 6.6 Antibody Fragments and ALPs Pipeline, 2014
Table 6.7 Pipeline Programmes with Limited Development, 2013-2014
Table 6.8 Antibody Fragments and ALPs Pipeline by Platform, 2014
Table 7.1 Top Ten Bestselling Biologics: Revenues ($m), 2012
Table 7.2 Biosimilar Antibodies Approved Worldwide, 2014
Table 7.3 Biosimilar Antibodies Submarket: Revenues ($m) and Submarket Shares (%) by Sector, 2012
Table 7.4 Biosimilar Antibodies Submarket: Overall Submarket and Revenue Forecasts ($m) by Drug, 2012-2024
Table 7.5 Patents Expiries for Leading Antibody Therapies in the US, EU and Japan, 2013-2022
Table 7.6 Reditux: Revenue ($m), 2008-2013
Table 7.7 Biosimilar Rituximab Pipeline, 2014
Table 7.8 Biosimilar Rituximab: Revenue Forecast ($m), 2012-2024
Table 7.9 Biosimilar Infliximab Pipeline, 2014
Table 7.10 Biosimilar Infliximab: Revenue Forecast ($m), 2012-2024
Table 7.11 Biosimilar Trastuzumab Pipeline, 2014
Table 7.12 Biosimilar Trastuzumab: Revenue Forecast ($m), 2012-2024
Table 7.13 Biosimilar Adalimumab Pipeline, 2014
Table 7.14 Biosimilar Adalimumab: Revenue Forecast ($m), 2012-2024
Table 8.1 World Next-Generation Antibody Therapies Market: Strengths and Weaknesses, 2014
Table 8.2 World Next-Generation Antibody Therapies Market: Opportunities and Threats, 2014-2024
Table 8.3 Big Pharma Acquisitions in the Next-Generation Antibodies Sector, 2005-2012
Table 8.4 World Next-Generation Antibody Therapies Market: STEP Analysis, 2014-2024
Table 8.5 Selected CMOs Investing in Next-Generation Antibody Technologies, 2005-2013
Table 8.6 Next-Generation Antibody Pipeline by Indication, 2014
Table 8.7 HER-Targeting Next-Generation Antibodies: Pipeline, 2014
Table 8.8 CD19- and CD20-Targeting Next-Generation Antibodies: Pipeline, 2014
Table 10.1 World Next-Generation Antibodies Market: Submarket Forecasts ($m) and Market Shares (%), 2012-2024
Table 10.2 Next-Generation Antibodies Pipeline by Phase, 2014
List of Figures
Figure 2.1 Next-Generation Antibody Therapies Market: Revenues ($m), 2008-2013
Figure 2.2 Next-Generation Antibody Therapies Market: Market Shares (%) by Sector, 2012
Figure 2.3 Antibody Therapies Market: Market Shares (%), 2012
Figure 2.4 Antibody Therapies Market Forecast ($m), 2012-2024
Figure 2.5 Next-Generation Antibodies Market: Revenue Forecast ($m), 2012-2024
Figure 2.6 Next-Generation Antibody Therapies: Market Drivers, 2014-2024
Figure 2.7 Next-Generation Antibody Therapies: Market Restraints, 2014-2024
Figure 2.8 Next-Generation Antibody Therapies: Market Shares (%) by Sector, 2018
Figure 2.9 Next-Generation Antibody Therapies: Market Shares (%) by Sector, 2024
Figure 2.10 Next-Generation Antibody Therapies: Market Shares (%) by Country/Region, 2012
Figure 2.11 US Next-Generation Antibody Therapies Submarket: Revenue Forecast ($m), 2012-2024
Figure 2.12 EU Next-Generation Antibody Therapies Submarket: Revenue Forecast ($m), 2012-2024
Figure 2.13 Next-Generation Antibody Therapies: Market Shares (%) by Country/Region, 2018
Figure 2.14 Next-Generation Antibody Therapies: Market Shares (%) by Country/Region, 2024
Figure 2.15 Japanese Next-Generation Antibody Therapies Submarket: Revenue Forecast ($m), 2012-2024
Figure 3.1 ADC Submarket: Revenues ($m) by Drug, 2011-2013
Figure 3.2 ADC Submarket: Revenue Forecast ($m), 2012-2024
Figure 3.3 ADC Submarket: Drivers and Restraints, 2014-2024
Figure 3.4 Adcetris: Revenue ($m) by Company, 2011-2013
Figure 3.5 Adcetris: Revenue Forecast ($m), 2012-2024
Figure 3.6 Kadcyla: Revenue ($m) by Quarter, 2013
Figure 3.7 Kadcyla: Revenue Forecast ($m), 2012-2024
Figure 3.8 ADC Pipeline by Platform, 2014
Figure 3.9 ADC Pipeline by Phase, 2014
Figure 3.10 ADC Pipeline by Indication, 2014
Figure 4.1 Engineered Antibodies Submarket: Revenue Forecast ($m), 2012-2024
Figure 4.2 Engineered Antibodies Submarket: Drivers and Restraints, 2014-2024
Figure 4.3 Poteligeo: Revenue ($m), 2012-2013
Figure 4.4 Poteligeo: Revenue Forecast ($m), 2012-2024
Figure 4.5 Gazyva: Revenue Forecast ($m), 2012-2024
Figure 4.6 Engineered Antibodies Pipeline by Technology Platform, 2014
Figure 4.7 Engineered Antibodies Pipeline by Indication, 2014
Figure 4.8 Engineered Antibodies Pipeline by Phase, 2014
Figure 5.1 Bispecific Antibodies Submarket: Revenue Forecast ($m), 2012-2024
Figure 5.2 Bispecific Antibodies Submarket: Drivers and Restraints, 2014-2024
Figure 5.3 Removab: Revenue ($m), 2010-2013
Figure 5.4 Removab: Revenue Forecast ($m), 2012-2024
Figure 5.5 Bispecific Antibodies Pipeline by Technology Platform, 2014
Figure 5.6 Bispecific Antibodies Pipeline by Phase, 2014
Figure 6.1 Kalbitor: Revenue ($m), 2011-2013
Figure 6.2 Kalbitor: Revenue Forecast ($m), 2012-2024
Figure 6.3 Antibody Fragments and ALPs Submarket: Revenue Forecast ($m), 2012-2024
Figure 6.4 Antibody Fragments and ALPS Submarket: Drivers and Restraints, 2014-2024
Figure 6.5 Antibody Fragments and ALPs Pipeline by Indication, 2014
Figure 6.6 Antibody Fragments and ALPs Pipeline by Platform, 2014
Figure 7.1 Biosimilar Antibodies Submarket by Sector, 2012
Figure 7.2 Biosimilar Antibodies Submarket: Revenue Forecast ($m), 2012-2024
Figure 7.3 Biosimilar Antibodies Submarket: Drivers and Restraints, 2014-2024
Figure 7.4 Reditux: Revenue ($m), 2008-2013
Figure 7.5 Biosimilar Rituximab: Revenue Forecast ($m), 2012-2024
Figure 7.6 Biosimilar Infliximab: Revenue Forecast ($m), 2012-2024
Figure 7.7 Biosimilar Trastuzumab: Revenue Forecast ($m), 2012-2024
Figure 7.8 Biosimilar Adalimumab: Revenue Forecast ($m), 2012-2024
Figure 8.1 Platforms Used for Clinical Development of Next-Generation Antibodies by Sector, 2014
Figure 8.2 Next-Generation Antibody Pipeline by Indication, 2014
Figure 10.1 Next-Generation Antibody Approvals, 2007-2014
Figure 10.2 Next-Generation Antibodies: Market Forecast ($m) by Sector, 2012-2024
Figure 10.3 Next-Generation Antibodies Pipeline by Phase, 2014
To see sample pages of this report please click here
AbbVie
Abgenix (part of Amgen)
Ablynx
Actavis
ADC Therapeutics
Adnexus (part of Bristol-Myers Squibb)
AET BioTech
Affibody
Affimed Therapeutics
Agensys (part of Astellas Pharma)
Alcon (part of Novartis)
Alexion Pharmaceuticals
Allergan
Allozyne
Ambrx
Amgen
AMRI
Aprogen
Arana Therapeutics (part of Cephalon)
Astellas Pharma
AstraZeneca
Auven Therapeutics
Bayer Healthcare
Biocad
Bioceros
Biocon
Biogen Idec
Biotest
BioWa (part of Kyowa Hakko Kirin)
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
BZL Biologics
Catalent Pharma Solutions
Celgene
Celldex Therapeutics
Celltech (part of UCB)
Celltrion
Cephalon (part of Teva)
CinnaGen
Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) [Mexico]
Concortis Biosystems (part of Sorrento Therapeutics)
Corixa
Covagen
Crescendo Biologics
CVie Therapeutics
CytomX Therapeutics
Daiichi Sankyo
Defiante Farmaceutica (part of Sigma-Tau)
Delenex Therapeutics
Dendreon
Domantis (part of GSK)
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Drug Controller General of India (DCGI)
Dyax
Eddingpharm
Egis Pharmaceuticals
Elan Pharmaceuticals
Eli Lilly
Epirus Biopharmaceuticals
ESBATech (part of Novartis)
ETH Zurich
European Medicines Agency (EMA)
EvaluatePharma (now Evaluate)
F-star
Five Prime Therapeutics
Food and Drug Administration (FDA) [US]
Fresenius Biotech (now named Neovii Biotech, part of Neopharm)
Fresenius Group
Fujifilm
Fujifilm Diosynth Biotechnologies
Fujifilm Kyowa Kirin Biologics
GE Healthcare
Gedeon Richter
Genentech (part of Roche)
Genmab
Gilead Sciences
GlycoExpress
Glycotope
GSK
Hanwha Chemical
Helmholtz Zentrum München
Hospira
IBC Pharmaceuticals (part of Immunomedics)
Igenica
Immunocore
ImmunoGen
Immunomedics
Intas Biopharmaceuticals
Isu Abxis
J&J
Janssen Biotech (part of J&J)
Janssen-Cilag (part of J&J)
KaloBios
Karolinska Institute
Kyowa Hakko Kirin
Kyowa Medex (part of Kyowa Hakko Kirin)
Laboratoires Français de Fractionnement et des Biotechnologies (LFB)
LFB Biomanufacturing (part of LFB)
Life Science Pharmaceuticals
LINDIS Biotech
LMC
Lonza
Mabion
MacroGenics
MedImmune (part of AstraZeneca)
Mentrik Biotech
Merck & Co.
Merck Serono
Merrimack Pharmaceuticals
Mersana Therapeutics
Merus Biopharmaceuticals
Micromet (part of Amgen)
Millennium Pharmaceuticals (part of Takeda)
Ministry of Food and Drug Safety (MFDS) [South Korea]
Ministry of Health [Brazil]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Molecular Partners
MorphoSys
Mylan
National Health Service (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nektar Therapeutics
Neopharm Group
Nichi-Iko Pharmaceutical
Novartis
Novellus Biopharma
Orygen Biotecnologia
Oxford BioMedica
Oxford BioTherapeutics
Pfizer
Pharmacyclics
PharmaPraxis
Pieris
Piramal Group
PlantForm
Probiomed
Progenics Pharmaceuticals
ProStrakan Group (part of Kyowa Hakko Kirin)
Ranbaxy Laboratories (part of Daiichi Sankyo)
Redwood Bioscience
Regeneron Pharmaceuticals
Reliance GeneMedix (part of Reliance Life Sciences)
Reliance Life Sciences
Roche
Roche Glycart (part of Roche)
Royal Institute of Technology (KTH) [Sweden]
SAFC
Samsung Bioepis
Samsung BioLogics
Sandoz (part of Novartis)
Sanofi
Scil Proteins
Seattle Genetics
Servier
Shanghai CP Guojian
Sigma-Tau Pharmaceuticals
Sorrento Therapeutics
Sothema Laboratories
Spectrum Pharmaceuticals
Spirogen (part of AstraZeneca)
Stada
Stelis Biopharmaceuticals (part of Strides Arcolab)
Strides Arcolab
Sutro Biopharma
Swedish Orphan Biovitrum (Sobi)
Swiss Federal Institute of Technology
Symphogen
Synthon
Synthon Biopharmaceuticals (part of Synthon)
Takeda Pharmaceutical Company
Talon Therapeutics (part of Spectrum Pharmaceuticals)
Targa Therapeutics
Teva Pharmaceutical Industries
TG Therapeutics
TRION Pharma
UCB
US Patent and Trademark Office
World Health Organization (WHO)
Wyeth (part of Pfizer)
Xencor
Zydus Cadila
To see sample pages of this report please click here
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
